We followed the treatment guidelines of our Ministry of Health, which were recommended and updated regularly by the National COVID\19 Scientific Committee, to treat our patients. they normalized in all patients (94.42??1%). None of them had fever after tocilizumab treatment and the levels of C\reactive protein (13.08??12.89) were almost within normal limits. Eosinophil values were quite low at the time of diagnosis (10??17.06), but increased significantly post\tocilizumab (155.33??192.69). There is currently no proven treatment for COVID\19 induced by novel coronavirus SARS\CoV\2. Based on our experience with twelve adult COVID\19 pneumonia patients, we can say that tocilizumab, an IL\6 inhibitor, is more beneficial in preventing the damage caused by excessive cytokine response in the body if administered at the right time and provides clinical and radiological recovery. strong class=”kwd-title” Keywords: COVID\19, Pneumonia, SARS\Cov\2, Tocilizumab 1.?INTRODUCTION The world began to receive news of a novel coronavirus that was unlike its previous forms in the Wuhan region of China in late December 2019. 1 Although this virus, which caused severe acute respiratory syndrome, was originally named 2019\nCov, later its name was changed to SARS\CoV\2, due to its similarities with the virus that caused the severe acute respiratory syndrome (SARS) epidemic in 2003. 2 , 3 This respiratory disease caused by SARS\CoV\2 started to be referred to as coronavirus disease 2019 (COVID\19). 4 The epidemic had now engulfed the whole world and on 10 March 2020, the World Health Organization declared a pandemic. 5 In the process since the isolation of SARS\CoV\2, no effective drug has yet been found to treat it completely. Many researchers around Col4a5 the world are investigating the effectiveness of dozens of drugs on COVID\19 and trying to find a solution to this disease. Antiviral agents such as lopinavir, ritonavir, 6 remdesivir, 7 antibacterial drugs such as macrolides, 8 antiparasitic drugs such as ivermectin, 9 antimalarial drugs such as hydroxychloroquine, 10 corticosteroids, and Succinyl phosphonate trisodium salt drugs with anti\inflammatory activities such as colchicine 11 are being investigated and their effectiveness is being discussed. Tocilizumab, a recombinant humanized anti\human interleukin\6 (IL\6) receptor monoclonal antibody, is also thought to be useful in COVID\19 treatment. 12 COVID\19 is clinically classified as a mild, moderate, severe, and critical disease. 13 When the disease has reached the modarete level, lung involvement is observed at various stages. 13 The reason why tocilizumab, a blocker of IL\6, is considered a promising treatment in COVID\19, is that SARS\CoV\2 causes a condition similar to the cytokine storm syndrome, and it is known that IL\6 plays a proinflamatory role in this inflammatory cascade. 12 Therefore, tocilizumab has begun to take its place in the treatment guidelines of several countries like China and Italy. 14 Since December 2019, the process of outbreak was being followed very closely by the Republic of Turkey, Ministry of Health. Precautions were taken against COVID\19 and preparations were made for the possibility of being involved in the pandemic. The first case in our country was reported on 10 March 2020. In our center, COVID\19 patients started to be admitted since 18 March 2020. We followed the treatment guidelines of our Ministry of Health, which were recommended and updated regularly by the National COVID\19 Scientific Committee, to treat our patients. In our country, as in China and Italy, tocilizumab was presented as a treatment option, considering that a cytokine storm was introduced during COVID\19. As of 18 March 2020, we started tocilizumab treatment to 12 patients who were admitted with COVID\19 pneumonia and thought to be in a cytokine storm. By sharing our experience in this clinical series, we aimed to guide at which point we should choose tocilizumab and what were the clinical, laboratory, and radiological outcomes. 2.?METHODS 2.1. Patients Twelve patients who were followed and treated with the diagnosis of COVID\19 pneumonia between 18 March and 8 April 2020 at Biruni University Faculty of Medicine Hospital Succinyl phosphonate trisodium salt (Istanbul, Turkey), and who received tocilizumab treatment because it was considered that they entered the cytokine storm during this period, were included in the study. Approval was obtained from the Biruni University Medical Research Ethics Committee for the study. Informed consent was obtained from all patients in that they agreed to publish their data in this case series. We will protect patients’ privacy and comply with the Helsinki Declaration. 2.2. Diagnosis Computed tomography (CT) of the thorax was done at the time of admission to all or any sufferers contained in the research. As recommended in the rules Succinyl phosphonate trisodium salt of our Ministry of Wellness, an oropharyngeal test was used using a swab, then.